Skip to main content
. Author manuscript; available in PMC: 2018 Dec 1.
Published in final edited form as: Cancer Immunol Res. 2017 Nov 2;5(12):1141–1151. doi: 10.1158/2326-6066.CIR-17-0235

Figure 3. Cisplatin and anti–PD-L1 blockade in combination delayed tumor growth and prolonged survival in MOC1 tumor-bearing mice.

Figure 3

Mice were injected with 5 × 106 MOC1 tumor cells in the right flank. After 11 days, mice with palpable tumors were randomized and treated concurrently with cisplatin (5 mg/kg/week × 4 weeks) and/or anti–PD-L1 antibody (200 mcg twice/week × 3 doses). Black line: control; Blue line: CDDP only; Gray line: anti–PD-L1; Green line: combination. A, Tumor volume over time. Data are mean ± SEM, n = 7–8 mice per group. *p<0.05, **p<0.01 vs. control by linear regression curve comparison B, Kaplan-Meier survival plot. *p<0.05 by log rank (Mantel-Cox) test.